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Long-term potentiation (LTP) of excitatory synaptic transmission has long been 20 
considered a cellular correlate for learning and memory1,2. Early LTP (eLTP, <1 hour) 21 
had initially been explained either by presynaptic increases in glutamate release3-5 or by 22 
direct modification of post-synaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 23 
acid receptor (AMPAR) function6,7. Compelling models have more recently proposed 24 
that synaptic potentiation can occur by the recruitment of additional post-synaptic 25 
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AMPARs8, sourced either from an intracellular reserve pool by exocytosis or from 26 
nearby extra synaptic receptors pre-existing on the neuronal surface9-12. However, the 27 
exact mechanism through which synapses can rapidly recruit new AMPARs during 28 
eLTP is still unknown. In particular, direct evidence for a pivotal role of AMPAR 29 
surface diffusion as a trafficking mechanism in synaptic plasticity is still lacking. Using 30 
AMPAR immobilization approaches, we show that interfering with AMPAR surface 31 
diffusion dramatically impaired synaptic potentiation of Schaffer 32 
collateral/commissural inputs to cornu ammonis area 1 (CA1) in cultured slices, acute 33 
slices and in vivo. Our data also identifies distinct contributions of various AMPAR 34 
trafficking routes to the temporal profile of synaptic potentiation. In addition, AMPAR 35 
immobilization in vivo in the dorsal hippocampus (DH) before fear conditioning, 36 
indicated that AMPAR diffusion is important for the early phase of contextual learning. 37 
Therefore, our results provide a direct demonstration that the recruitment of new 38 
receptors to synapses by surface diffusion is a critical mechanism for the expression of 39 
LTP and hippocampal learning. Since AMPAR surface diffusion is dictated by weak 40 
Brownian forces that are readily perturbed by protein-protein interactions, we 41 
anticipate that this fundamental trafficking mechanism will be a key target for 42 
modulating synaptic potentiation and learning.  43 
 44 
Hebbian LTP is characterized by a prolonged increase in a synaptic response that occurs upon 45 
robust, coincident activation of pre-and post-synaptic neurons. The induction of canonical 46 
LTP proceeds by calcium influx through N-methyl-D-aspartate receptors (NMDARs) and 47 
subsequent activation of calcium/calmodulin-dependent kinase II (CaMKII)6,8. However, 48 
despite decades of intense research on synaptic plasticity focused on the Schaffer 49 
collateral/commissural synapses, there is still ambiguity over how canonical LTP is 50 
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ultimately expressed13. A substantial body of evidence points to post-synaptic mechanisms8, 51 
where the prime candidates have been an increase in the conductance or number of 52 
AMPARs6-8. Synaptic recruitment of additional receptors had initially been proposed to 53 
originate from stimulus-induced AMPAR exocytosis from intracellular stores14-17. However, 54 
work from our lab and others have shown that there is a large amount of extra-synaptic 55 
surface AMPARs in hippocampal neurons and that a large fraction of them diffuse almost 56 
freely by Brownian motion before being reversibly confined and trapped at synapses10,12. 57 
Furthermore, activity dependent activation of CaMKII induces rapid immobilization of 58 
AMPAR at synapses10,18 and recent work implicates a pre-existing extra-synaptic receptor 59 
pool in the expression of LTP19. Both lateral movement and exocytosis of AMPAR could 60 
indeed contribute to LTP20. Altogether, this led us to directly investigate the contribution of 61 
AMPAR surface diffusion to synaptic potentiation. 62 
We developed manipulations that cross-link (X-link) surface AMPARs, thereby preventing 63 
their diffusion on the cell membrane. First, we created a construct to autonomously express 64 
recombinant biotin-tethered GluA2 subunits21, which we could surface X-link by tetrameric 65 
biotin-binding proteins (~60 kDa, Fig. 1a-b). We transfected bAP::SEP::GluA subunits into 66 
cultured hippocampal neurons and monitored their surface diffusion by fluorescence recovery 67 
after photo-bleaching (FRAP). Brief pre-treatment of cultures with neutravidin (NA) 68 
significantly inhibited FRAP at dendritic spines (Fig. 1c-d), only if both the AP tag was 69 
included and the biotin ligase BirA-ER was co-expressed (Fig. 1d). Therefore, we could 70 
effectively manipulate post-synaptic AMPAR surface diffusion by a specific X-linking 71 
approach. Similar neutravidin-induced immobilization of AMPARs was obtained when 72 
measured by tracking bAP::SEP::GluA2 diffusion with quantum dots (Extended Data Fig. 1). 73 
Much of our current understanding of LTP mechanisms comes from experiments on in vitro 74 
hippocampal slice preparations. We achieved effective molecular replacement of endogenous 75 
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receptors by delivering bAP::SEP::GluA2 into CA1 neurons of slice cultures from Gria2-/- 76 
mice. In wild-type mice, principal neurons of the hippocampus predominantly express hetero-77 
tetrameric AMPARs composed of the GluA1 and GluA2 subunits, which have a linear 78 
current-voltage (I-V) relationship (Fig. 1e, grey). In contrast, AMPAR currents in the absence 79 
of GluA2 are inwardly rectifying (Fig. 1e, red)22. Expression of bAP::SEP::GluA2 faithfully 80 
restored a linear I-V relationships in the Gria2-/- slices for both synaptic currents (Fig. 1e, top, 81 
green) and extra-synaptic glutamate uncaging currents to near wild-type levels (Fig. 1e, 82 
bottom, green). We also confirmed that biotin-binding proteins could effectively diffuse 83 
through organotypic slices and bind specifically to molecularly replaced neurons (Extended 84 
Data Fig. 2a). Importantly, following this expression manipulation, we could obtain stable 85 
synaptic EPSPs (Extended Data Fig. 2b) and reliably induce synaptic potentiation by 86 
applying high frequency stimulation (HFS) (Fig. 2a). 87 
We next evaluated the effect of AMPAR X-linking on synaptic transmission and potentiation. 88 
Acute pre-treatment followed by wash of transfected slice cultures with NA to X-link only 89 
pre-existing surface AMPARs had no detectable effects on basal synaptic transmission (Fig. 90 
1f , top and middle, Extended Data Fig. 2c, e) or surface AMPAR levels (Fig. 1f, bottom). 91 
However, this pre-treatment with NA completely abolished the short-term potentiation (STP) 92 
induced by HFS (Fig. 2b). The impaired potentiation was likely not due to failure to reach 93 
induction threshold since we could not detect significant effects of NA on post-synaptic 94 
depolarisation during HFS (Extended Data Fig. 2d) or on the average size of the EPSP during 95 
the baseline (Extended Data Fig. 2e). Furthermore, the amplitude and time course of synaptic 96 
NMDA receptor currents in bAP::SEP::GluA2 replacement cells were unaffected by the X-97 
link manipulation (Fig. 1f; Extended Data Fig. 2f). Finally, we confirmed that the effect of 98 
NA required specific interactions with bAP::SEP::GluA2 by showing that potentiation was 99 
normal in neurons co-expressing myc::SEP::GluA2 (which does not bind NA) and BirA-ER 100 
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in NA-treated slices (Extended Data Fig. 3a). These results suggest that diffusion of a pre-101 
existing surface pool of post-synaptic AMPARs plays a critical role in the expression of 102 
synaptic potentiation. 103 
While fully abolishing STP, X-link pre-treatment still allowed the slow development of a 104 
significant, albeit smaller, eLTP (Fig. 2b). This prompted us to evaluate the contribution of 105 
different AMPAR trafficking steps in shaping the temporal profile of synaptic potentiation. 106 
Previous reports described intact STP following intracellular injection of neurotoxins, which 107 
prevent post-synaptic membrane fusion events and LTP14, or more recently following the 108 
specific knock out of the exocytic machinery17. After reproducing this ourselves using 109 
Tetanus Toxin light chain (TeTx, Fig. 2c; Extended Data Fig. 3b), we posited that expression 110 
of synaptic potentiation only at later time periods is contributed by exocytosis of new 111 
AMPARs to the cell surface. Consistent with this, gradual run-up of synaptic transmission 112 
after HFS in slices pre-incubated with NA was blocked by either intracellular TeTx (Fig. 2d) 113 
or N-ethylmaleimide (NEM) (Extended Data Fig. 3c). Newly exocytosed receptors might also 114 
require surface diffusion as an intermediate step for synaptic recruitment since exocytosis has 115 
been proposed to occur away from synapses15,20,23. Indeed, the presence of low concentrations 116 
of NA in the extracellular recording solution following NA pre-treatment of slices prevented 117 
both STP and eLTP (Fig. 2e). Since we could not detect an effect of our post-synaptic 118 
manipulation on presynaptic parameters (Extended Data Fig. 4), these data reveal a 119 
preferential contribution of mobile post-synaptic AMPARs sourced from pre-existing surface 120 
and intracellular pools to establishing STP and sustaining eLTP, respectively (Extended Data 121 
Fig. 5).   122 
To confirm that AMPAR diffusion is an important trafficking step for endogenous AMPARs 123 
during the expression of synaptic potentiation, we used a classical antibody X-linking 124 
approach. In cultured hippocampal neurons, single-layer X-link using an immunoglobulin G 125 
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(IgG) against GluA2 was also effective at limiting the surface diffusion of AMPARs 126 
(Extended Data Fig. 1 and 6) without modifying their endocytosis or phosphorylation status 127 
(Extended Data Fig. 7). Pre-injection of neither X-linking anti-GluA2 IgG nor their 128 
monovalent control fragment antigen binding (Fab) fragments into CA1 of acute 129 
hippocampal slices had any effect on basal synaptic transmission (Extended Data Fig. 8a, c-130 
f). In contrast, strong attenuation of STP induced by HFS was observed with the IgG but not 131 
the Fab, without affecting the HFS-induced decrease in paired pulse ratio, which measures 132 
the pre-synaptic component to synaptic potentiation (Extended Data Fig. 8b). Strikingly, 133 
eLTP induced by HFS or theta burst stimulation (TBS) was completely abolished when the 134 
antibody was infused continuously in the slice (Fig. 3b-c, Extended Data Fig. 9). 135 
We then confirmed that endogenous AMPAR diffusion is an important trafficking step for 136 
eLTP in vivo (Fig. 3d). In contrast to the Fab fragments (Fig. 3e) and control IgG (Fig. 3g), 137 
injection of anti-GluA2 IgG into the CA1 area of the dorsal hippocampus (DH) (Fig. 3f) 138 
caused a striking attenuation of fEPSP potentiation following strong commissural stimulation 139 
(Fig. 3h). 140 
The DH is a key structure for acquiring and memorizing contextual aspects of fear 141 
memories24,25 and these processes have been tied to AMPAR trafficking and synaptic 142 
potentiation in vivo26,27,28. Therefore, we reasoned that X-linking surface AMPARs in the 143 
adult DH could impair the ability of mice to form contextual fear memories.  144 
Compared to anti-GluA2 Fab fragments and denatured IgG (Fig. 4a1), mice injected in the 145 
DH with anti-GluA2 IgG exhibited half the level of freezing when re-exposed to the 146 
conditioning context a day later (context A in Fig. 4a1). After 2-3 days of recovery, a second 147 
contextual conditioning performed on the same mice allowed robust fear learning (context C 148 
in Fig. 4a1). None of the mouse groups exhibited contextual generalization (context B in Fig. 149 
4a1). The effect of IgG was not a temporary impairment of the mice to express conditioned 150 
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fear responses since all groups performed well in hippocampus-independent, cued fear 151 
memory tests (Fig. 4a2). We ruled out a more general impairment of hippocampus function 152 
from the X-link by infusing antibodies before testing and showing that recall of contextual 153 
fear memories was similar between anti-GluA2 IgG and Fab (Fig. 4b). 154 
Our experiments demonstrate that recruitment of diffusing surface AMPARs is an essential 155 
mechanism for eLTP, both in brain slices and in vivo and underlies early phases of 156 
hippocampal-dependent fear learning. Our observations provide direct evidence for a model 157 
in which rapid but temporary recruitment of AMPARs from a surface pool to synaptic sites 158 
by lateral movement and activity-dependent trapping at the post-synaptic density mediates 159 
the earlier phase of synaptic potentiation. This would then be followed by replenishment of 160 
the extracellular pool by exocytosis of AMPARs, which also need to diffuse to reach synaptic 161 
sites and sustain synaptic potentiation. That manipulating AMPAR surface diffusion in vivo 162 
specifically affects learning without modifying basal transmission opens the way to new 163 
approaches to manipulate synaptic memory. 164 
  165 
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FIGURE 1. Biotin-tethered AMPARs are effectively X-linked by neutravidin to prevent 166 
their surface diffusion. a, Construct for dual expression of tagged AMPARs 167 
(AP::SEP::GluA) and the biotinylation enzyme (BirA-ER). b, Strategy to X-link biotinylated 168 
AMPAR subunits (bAP::SEP::GluA) (AP = acceptor peptide; SEP = Super-Ecliptic 169 
pHluorin; IRES = internal ribosome entry site). c, Example images (top) and graph showing 170 
mean FRAP curves, fits and standard error bands (bottom) for control and pre-treatment with 171 
neutravidin (50 nM NA for 2 min). Inverted image lookup table. d, Receptor mobile fraction 172 
in spines of cells expressing AP::SEP::GluA1 and AP::SEP::GluA2 is reduced by NA pre-173 
treatment and depends on the AP tag and BirA-ER. e, Molecular replacement with 174 
bAP::SEP::GluA2 in CA1 neurons. Example AMPAR current traces from Schaffer collateral 175 
(SC) synapse stimulation (top) or by 1-photon glutamate uncaging on the soma (bottom). f, 176 
Pre-treating slices with NA (100 nM for 45 min) caused no detectable effect on: Top. 177 
AMPA/NMDA ratios, Middle, evoked EPSCs, or Bottom, glutamate uncaging responses. All 178 
bar graphs show marginal means with 84% confidence intervals (d) or Least Significant 179 
Difference (LSD) error bars (e-f). Statistical significance was assessed by mixed model 180 
nested ANOVA (d), 1-way ANOVA (e) or 2-way ANOVA with Holm-Bonferroni post-tests 181 
(f; ns = not significant, ** P < 0.01; *** P < 0.001). 182 
 183 
  184 
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FIGURE 2. X-link reveals surface diffusion as a critical step in the synaptic delivery of 185 
AMPARs during synaptic potentiation. Top, Scheme illustrates experimental protocols on 186 
organotypic Hippocampal slices. a-e, Left, Example whole-cell voltage traces and summary 187 
plots of mean normalized EPSP slope ± SEM. (HFS = high-frequency stimulation). Middle, 188 
Cumulative histograms for average normalized EPSP slope during STP and LTP. Right, 189 
Models of experimental manipulations. a, Robust STP and LTP following HFS under control 190 
conditions. b, Detectable HFS-induced LTP but not STP in slices pre-treated with 100 nM 191 
neutravidin (NA). c, Severe attenuation of LTP but not STP with 0.5 μM intracellular TeTx. 192 
d-e, No detectable change in EPSP slope after HFS when 100 nM NA pre-treatment is 193 
combined with either: d, TeTx in intracellular recording solution, or e, continuous infusion of 194 
10 pM NA in the external recording solution. Statistical significance was assessed by 195 
repeated measures (RM)-ANOVA with Holm-Bonferroni post-tests (a-e; ns = not significant, 196 
* P < 0.05; ** P < 0.01). 197 
 198 
FIGURE 3. Antibody X-link of endogenous GluA2 attenuates long-term potentiation of 199 
CA1 fEPSPs in vitro and in vivo. a Acute slice experimental setup and antibody labelling 200 
controls. b-c Protocol (top), example traces (middle) and summary plots of mean normalized 201 
fEPSP slope ± SEM. (Ab = antibody). No stable synaptic potentiation following high 202 
frequency stimulation (HFS, b) or theta-burst stimulation (TBS, c) when α-GluA2 IgG pre-203 
injection is combined with continuous infusion of the antibody. d In vivo experimental 204 
protocol and histological controls. (VHC = ventral hippocampal commissure; Ab = antibody). 205 
e-h LTP recordings following injection of: e, anti-GluA2 Fab; f, anti-GluA2 IgG or g, control 206 
IgG. Left, Mean normalized fEPSP slope ± SEM. Right. Example voltage traces before and 207 
after HFS. h, Bar graph of the mean and data points for the normalized fEPSP slope 208 
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potentiation. Statistical significance was assessed by 1-way ANOVA with Holm-Bonferroni 209 
post-tests (h, ns = not significant, * P < 0.05; ** P < 0.01) 210 
  211 
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FIGURE 4. Impairment of a hippocampal-dependent learning task by infusion of X-212 
linking anti-GluA2 IgG. Shaded data are controls for baseline freezing levels. Unshaded 213 
data were used for hypothesis testing. a, Selective effects on contextual (a1) versus cued (a2) 214 
fear learning. a1, Left, Antibody infusion sites. Right, Pre-conditioning infusion of anti-215 
GluA2 IgG reduces freezing to conditioned context (A). a2, Cued fear learning was robust for 216 
all antibodies. b, No detectable difference in freezing to conditioned context between 217 
antibodies for pre-test infusions. All bar graphs show means ± SEM error bars. Statistical 218 
significance was assessed by 2-way RM-ANOVA with Holm-Bonferroni post-tests (ns = not 219 
significant, ** P < 0.01; *** P < 0.001) 220 
 221 
  222 
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Online Content Methods, along with any additional Extended Data display items and 223 
Source Data, are available in the online version of the paper; references unique to 224 
these sections appear only in the online paper. 225 
  226 
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Extended data figure legends 256 
EXTENDED DATA FIGURE 1. X-link of AMPA receptors in cultured hippocampal 257 
neurons measured by quantum dot tracking. a Neutravidin and anti-GluA2 IgG (clone 258 
14B11) X-linking, to a similar extent, reduce the surface diffusion of bAP::SEP::GluA2 259 
expressed in rat hippocampal neurons as measured by quantum dot tracking. Relative 260 
frequency histogram (left) of log-transformed diffusion coefficients (D), bar chart of mobile 261 
fraction (middle) and a plot of group data for mean-squared displacement (MSD) curves of all 262 
trajectories (right). Control was no antibody. Statistical significance was assessed by 1-way 263 
ANOVA with Holm-Bonferroni post-tests (ns = not significant, ** P < 0.01; *** P < 0.001). 264 
 265 
EXTENDED DATA FIGURE 2. Controls relating to X-link by pre-treating 266 
bAP::SEP::GluA2-transfected slices cultures with neutravidin. a, Biotin-binding proteins 267 
diffuse through living organotypic slices and bind specifically to bAP::SEP::GluA2-268 
expressing cells. Images show a maximum projection of an example 6.6 micron Z-stack in a 269 
transfected Gria2-/- organotypic slice. CA1 neurons were cotransfected with tdTomato and 270 
bAP::SEP::GluA2. Streptavidin AF-633 staining was observed in all 12 bAP::SEP::GluA2-271 
transfected CA1/3 cells observed and imaged. In contrast, no surface staining was observed 272 
in 5 CA1/3 cells transfected with myc::SEP::GluA2. b-c Summary plots of mean normalised 273 
EPSP slope ± SEM from whole cell-recordings of neurons in CA1. Stable baseline 274 
transmission in bAP::SEP::GluA2 replacement cells (without high-frequency stimulation, i.e. 275 
pseudo (p)HFS) in slices either with (c) or without NA-pretreatment (b). d, Top, 276 
Superimposed post-synaptic response of each cell during the first HFS train (grey) for Ctl and 277 
NA pre-treatment groups; the average responses (after spikes were removed using a median 278 
filter with window width ranging from 2-6 ms) are shown in black and blue respectively. 279 
Bottom, Bar graph showing no significant effect detected for NA pre-treatment on the area-280 
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under-curve (AUC) of the post-synaptic depolarization recorded across the three HFS trains 281 
used to induce synaptic potentiation. e, Bar graph showing no significant effect of NA pre-282 
treatment on the EPSP slope during the baseline recording. f, No significant effect of NA pre-283 
treatment on the amplitude and time course of NMDAR currents is detected in 284 
bAP::SEP::GluA2 replacement cells. Top, Evoked NMDAR EPSCs were simultaneously 285 
recorded in bAP::SEP::GluA2-transfected and neighbouring untransfected cells of Gria2-/- 286 
slices. Example NMDAR-mediated EPSC recordings from transfected cells in Ctl (left) and 287 
NA pre-treatment (right). Two-exponent fits to the decay (dashed red lines) and the weighted 288 
average (bold red line) are superimposed over the traces. Bottom, Scatter plots of NMDAR 289 
EPSC amplitude (above) and decay time constant (below) for transfected and untransfected 290 
cells from the Ctrl (left) and NA pre-treatment (right). Bold line represents the line of unity. 291 
Dashed lines represent 95 % confidence bands from linear fits through the origin. The line of 292 
unity is between the confidence bounds in all cases. All bar graphs show marginal means 293 
with Least Significant Difference (LSD) error bars (d-e). Statistical significance was assessed 294 
by mixed model nested ANOVA (d) or 2-way ANOVA without interaction (e; ns = not 295 
significant, * P < 0.05). 296 
 297 
EXTENDED DATA FIGURE 3. Controls relating to manipulations preventing 298 
AMPAR diffusion and exocytosis. Left, Summary plots of mean normalized EPSP slope ± 299 
SEM. (HFS = high-frequency stimulation). Right, Cumulative histograms for average 300 
normalized EPSP slope during STP and LTP. a, Robust STP and LTP following HFS in 301 
myc::SEP::GluA2 replacement cells following NA pre-treatment. b Rundown of basal 302 
transmission by 0.5 µM intracellular TeTx during pseudo (p)HFS recordings of 303 
bAP::SEP::GluA2 replacement cells. c, Absent potentiation following HFS in 304 
bAP::SEP::GluA2 replacement cells when NA pre-treatment is combined with intracellular 305 
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500 µM NEM. Statistical significance was assessed by RM- ANOVA (a-c; ns = not 306 
significant, * P < 0.05; ** P < 0.01). 307 
 308 
EXTENDED DATA FIGURE 4. Presynaptic plasticity controls for neutravidin X-link 309 
bAP::SEP::GluA2. a Neutravidin has effect on paired-pulse ratio (PPR) of: a, the slope of 310 
AMPA-mediated EPSPs evoked at 50 ms intervals in untransfected CA1 pyramidal neurons. 311 
b, the amplitude of NMDA-mediated EPSCs evoked at 50 ms intervals. Statistical 312 
significance was assessed by unpaired t-tests (a-b; ns = not significant). 313 
 314 
EXTENDED DATA FIGURE 5. Statistical comparison between all the different 315 
treatments for STP and LTP. Bar graph summarizing statistical comparison of the data for 316 
the manipulations in Fig. 2a-e, Extended Data Fig. 2b-c and Extended Data Fig. 3a-c. 317 
Different AMPAR trafficking manipulations have distinct effects on synaptic potentiation. 318 
The results demonstrate that HFS-dependent STP is only significantly different from control 319 
when surface diffusion of existing surface AMPARs is prevented. In contrast, HFS-320 
dependent LTP is significantly different only for manipulations that prevent the delivery of 321 
newly exocytosed receptors. Statistical significance was assessed by 2-way RM-ANOVA 322 
with Benjamini and Hochberg post-tests (ns = not significant, * P < 0.05; ** P < 0.01; *** P 323 
< 0.001). 324 
 325 
EXTENDED DATA FIGURE 6. Control experiments for antibody-mediated X-link of 326 
AMPA receptors in cultured hippocampal neurons. a Anti-GluA2 IgG (bivalent) but not 327 
Fab (monovalent) prevents normal FRAP of spine SEP-GluA2. Graphs show ensemble grand 328 
mean FRAP curves, fits and standard error bands for experiments using transfected cultures 329 
pre-treated for half an hour with 80 mg/L anti-GluA2 Fab clone 15F1 (Top), 80 mg/L anti-330 
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GluA2 IgG clone 15F1 (Middle) or vehicle (Bottom). b-c Relative frequency histogram of 331 
log-transformed diffusion coefficients (D, left) and scatter dot bar graph of percentage mobile 332 
fractions obtained from single-particle tracking (SPT) experiments. b U-PAINT single 333 
particle tracking of endogenous GluA2 in the presence or absence of anti-GluA2 IgG clone 334 
14B11. c PALM single particle tracking of expressed mGluR5::mEOS in the presence or 335 
absence of anti-GluA2 IgG clone 14B11. Statistical significance was assessed by unpaired t-336 
tests (b-c, ns = not significant, *** P < 0.001). 337 
 338 
EXTENDED DATA FIGURE 7. No detectable effect of incubation with X-linking anti-339 
GluA2 IgG on basal endocytosis or phosphorylation of GluA1-containing AMPA 340 
receptors. a Schematic of the experimental protocol performed on DIV 17 cultured 341 
hippocampal neurons and data summary of fluorescence (normalized to the mean 342 
fluorescence at time zero) for anti GluA1 antibody feeding 30 minutes following 15 minute 343 
X-link by 10 µg/ml anti-GluA2 IgG (clone 15F1). Note that most GluA1 AMPA receptors in 344 
pyramidal neurons exist as GluA1/2 heteromers. Similar results were obtained from two 345 
experiments and combined, where the control was either: 1) no antibody; or 2) anti-GFP. The 346 
images are all scaled the same. b Schematic of experimental protocol (top), images of 347 
example Western blots (middle) and data for phosphorylation at GluA1 serine 845 and 831 348 
after 15 minute X-link by 10 µg/ml anti-GluA2 IgG (clone 15F1) or control IgG (anti-GFP). 349 
Phosphorylation was unaffected by the X-link manipulation. c. Schematic of experimental 350 
cLTP protocol (top), images of example Western blots (middle) and data for phosphorylation 351 
at GluA1 serine 845 after 15 minute X-link by 10 µg/ml anti-GluA2 IgG (clone 15F1) or 352 
control IgG (anti-GFP) followed by chemical LTP (cLTP) or control treatment. The X-link 353 
manipulation had little impact on S845 phosphorylation induced by cLTP. We achieved 354 
similar phosphorylation results for AMPARs isolated by surface biotinylation and eluting 355 
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from streptavidin beads. All bar graphs show marginal means with 84% confidence intervals 356 
(a) or Fisher’s Least Significant Difference (LSD) error bars (b-c). Statistical significance 357 
was assessed by mixed model nested ANOVA (a), 2-way ANOVA without interaction (b) or 358 
2-way RM-ANOVA (ns = not significant, *** P < 0.001). 359 
 360 
EXTENDED DATA FIGURE 8. Effect of X-linking AMPA receptors on synaptic 361 
potentiation and basal transmission in acute hippocampal slices. a Schematic diagram 362 
illustrating the protocol for pre-injection antibody X-link experiments in acute slices. b 363 
Summary plots of mean normalised fEPSP slope (top) and paired-pulse ratio (PPR, 200 ms 364 
interval) of the slope (bottom) ± SEM. c Input-output curves of the field EPSP slope are 365 
unaffected by antibody infusion. The fiber volley varied linearly over the range of stimulation 366 
intensities (data not shown). d Input-output curves of evoked NMDAR-mediated EPSCs are 367 
unaffected by antibody infusion. e Spontaneous EPSC frequency (left) and amplitude (right) 368 
are unaffected by antibody infusion.  f NMDA/AMPA ratios are unaffected by antibody 369 
infusion. ANOVA on log10(ratio NMDA/AMPA), F(2,54) = 0.53, P = 0.5942. d-g, Note that 370 
measurements from cells within the same slice were averaged before performing statistics. 371 
Numbers in brackets indicates the number of cells. All graphs show data represented using 372 
box-and-whisker (10-90 %) plots. Statistical significance was assessed by 1-way ANCOVA 373 
(c-d) or 1-way ANOVA (e-f) 374 
 375 
EXTENDED DATA FIGURE 9. Cumulative histograms for the average normalized EPSP 376 
slope during STP and LTP from the HFS- and TBS-induced synaptic potentiation 377 
experiments summarised in Fig 3b and c respectively. 378 
 379 
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Supplementary methods 
Reagents 
Monoclonal whole IgG1-κ and Fab fragments recognising the extracellular domain of GluA2 (clones 
15F1 and 14B11, gifts from E. Gouaux), were prepared	using the purified GluA2 receptor in detergent 
solution as the antigen29. Control antibody for in vivo LTP experiments was polyclonal goat anti-rat IgG 
(112-005-071, Jackson). Antibodies were stored at -80 °C and at 2.9-5.8 mg/ml in phosphate buffered 
saline (PBS) containing (in mM): NaCl (50), Na-phosphate (30, pH 7.4). For the denatured antibody 
control, the anti-GluA2 IgG was incubated at 100 °C for 10 minutes. The anti-GFP whole IgG1-κ was 
from murine clones 7.1 and 13.1 (11814450001, Roche). The antibody lyophilizate was reconstituted 
at 2.9 mg/ml in water and the buffer was exchanged by dialysis (overnight at 4 °C, 3500 MWCO) with 
PBS and the concentration re-adjusted to ~2.9 mg/ml.  
The unlabelled, non-glycosylated form of avidin (Neutravidin) was purchased from Invitrogen. 
Recombinant light chain of tetanus toxin was either purchased from (Quadratech Diagnostics Ltd.) or 
obtained as a gift from T. Galli. All solutions were prepared in MilliQ water (18.2 MW × cm) with salts 
purchased from Sigma-Aldrich. Chemicals used for intracellular patchclamp recording solutions were 
trace metal grade purity. All drugs were purchased from Tocris Bioscience.  
 
Molecular biology 
An Ig κ-chain signal sequence (METDTLLLWVLLLWVPGSTGDG), AP tag 
(GGLNDIFEAQKIEWHEGATG) and SEP were cloned in-frame with the 5'-end of the coding 
sequence for the mature rat GluA1 and 2 subunit proteins. The entire open reading frames (ORFs) were 
cloned upstream (5’) of an encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES) 
sequence. The BirA-ER coding sequence30 (a gift from A. Ting, MIT Cambridge) was then cloned to 
the 3' end of the IRES such that the start codon of the BirA-ER signal sequence corresponded to the 
11th ATG of the IRES sequence. Doxycycline-dependent expression of the resulting dual-construct 
bAP::SEP::GluA was achieved by cloning the entire AP::SEP::GluA IRES BirA-ER sequence into the 
multiple cloning site of the pBI vector (BD Bioscience) and co-transfecting it with approximately equal 
molar quantities of rtTA-transactivator. The GluA2 subunit used was edited at the Q/R site (R607), 
unedited at the R/G site (R764) and the ligand-binding domain splice variant was flop except for residue 
S775 (flip), where amino acid numbering corresponds to the coding sequence of the immature GluA2 
peptide (NP_001077280.1). The GluA1 subunit used was flip splice variant. Plasmid DNA was 
prepared using endotoxin-free MaxiPreps (Qiagen). All constructs were verified by restriction enzyme 
digest patterns and Sanger DNA sequencing.  
Animals 
GluA2 knockout mice31 used for slice culture experiments were bred on a swiss-type NMRI 
background, where the impact of the mutation on weight, height, growth and fertility were weaker than 
on the original background strain. Gria2-/- pups identified by genotyping were obtained from 
heterozygote matings. In vivo recordings and behaviour experiments were performed on 2–3 month old 
male C57BL6/J mice, housed in 12/12 Light/Dark with ad libitum feeding. Every effort was made to 
minimize the number of animals used and their suffering. The experimental designs and all procedures 
were in accordance with the European guide for the care and use of laboratory animals and the animal 
care guidelines issued by the animal experimental committee of Bordeaux Universities (CE50; 
A5012009). 
 
Dissociated neuron cultures 
Banker cultures of hippocampal neurons from E18 Sprague-Dawley rat embryos of either sex were 
prepared at a density of 200,000 cells per 60-mm dish on poly-L-lysine pre-coated 1.5H coverslips 
(Marienfeld, cat. No. 117 580). Neuron cultures were maintained in Neurobasal medium supplemented 
with 2 mM L-glutamine and 1X Neuromix supplement (PAA). After 48 hours, 5 µM Ara-C (Sigma-
Aldrich) was added to the culture medium. Astrocyte feeder layers were prepared from the embryos the 
same age at a density of 20,000 to 40,000 cells per 60-mm dish (per the Horse Serum batch used) and 
cultured in MEM (Fisher Scientific, cat. No. 21090-022) containing 4.5g/l Glucose, 2 mM L-glutamine 
and 10% horse serum (Invitrogen) for 14 days. 
 
Fluorescence Recovery after Photobleaching 
Banker cultures were transfected at 11 days in vitro (DIV) using Effectene (Qiagen N.V., Venlo, 
Netherlands). Doxycycline (1 μg/ml) was added to the culture medium 24-48 hours before experiments 
using inducible GluA2 constructs. Coverslips of transfected neurons (14-16 DIV) were mounted in a 
Ludin chamber (Life Imaging Services) and transferred to an inverted microscope (Leica, DMI 6000B) 
maintained near-physiological temperature with a microscope temperature control system (Life 
Imaging Services, Cube 2). The chamber was perfused at 1 mg/ml (Gilson MiniPuls3) with extracellular 
solution containing (in mM): NaCl (145), KCl (3.5), MgCl2 (2), CaCl2 (2), D-glucose (10), HEPES (10) 
(pH 7.4, ~300 mOsm) and the preparation was observed through a 63x oil objective (Leica, HCX PL 
APO CS, Iris NA 1.4-0.6). Transfected cells were identified under epifluorescence (Leica EL6000) and 
illuminated with 473 nm laser light using a high-speed spinning disk confocal scanner unit (Yokogawa 
CSU22) for acquisition. Emission was captured with an electron multiplying charge-coupled device 
(EMCCD) camera (Photometrics Quantem 512SC) and data was stored on the hard disk of a personal 
computer (DELL Precision, Precision PWS690). Hardware was controlled with MetaMorph software 
(Molecular Devices, v7.1.7) and ILAS system software (Roper).  
Images of SEP-GluA1 expressing neurons were acquired before and after perfusion of 2 ml of 
fluorescently-labelled biotin-binding proteins and then washed for 5 minutes with Tyrode’s solution. 
Following the wash, using an exposure time of 0.5 seconds, the protocol consisted of: 1) acquiring 11 
images at 0.67 s intervals; 2) photobleaching the regions of interest (ROI), then 3) acquiring 40 images 
at 0.67 s intervals and a further 55 images at 5 s intervals. For bleaching, we used a 5 ms pulse of 488 
nm laser light (Coherent Sapphire CDRH 100 mW) set to ~3.7 mW laser power at the back of the 
objective, which was sufficient to reduce fluorescence by ~50 %. A FRAP head (Roper/Errol) was used 
to scan ROIs (~0.690 µm diameter) with the bleaching laser. ROIs were positioned over a small number 
of independent spines across the field of view. Finally, at the end of the experiment, we obtained an 
image before and after application of membrane impermeant GFP quencher (5 mM Trypan red) to 
confirm that most of the SEP fluorescence was on the cell surface. Time-lapse images were corrected 
for XY-drift observational and bleach-pulse photobleaching32 using macros in either MetaMorph 
(Molecular Devices) or ImageJ (http://imagej.nih.gov/ij/). ROIs of fixed diameter (10 pixels, eq. to 2.3 
µm) were then carefully positioned over each bleached spine head and the integrated or mean 
fluorescence intensity was measured for every image. The fluorescence intensity for each ROI was 
subjected to full scale normalization by subtracting the average fluorescence intensity of the pre-bleach 
images and dividing the result by the fluorescence of the first post-bleach image. 
 
Organotypic slice preparation and transfection 
Hippocampi were dissected from Gria2 mice (either sex) at postnatal age 6–8 in modified Gey's 
balanced salt solution as described33. Transverse slices were cut with a tissue chopper (McIlwain) and 
positioned on small membrane segments (FHLC01300, Millipore) and culture inserts (PICM0RG50, 
Millipore) in 6-well plates containing 1 ml/well slice culture medium, which was minimum essential 
medium (MEM) supplemented with 15 % heat-inactivated horse serum, 0.25 mM ascorbic acid, 3 mM 
L-glutamine, 1 mM CaCl2, 1 mM MgSO4, 25 mM HEPES and 5 g/L D-Glucose. Slices were maintained 
in an incubator at 34 °C with 5 % CO2 and the culture medium was replaced every 3-4 days. One week 
after plating, slices were individually transferred to the chamber of an upright microscope (Eclipse FN1, 
Nikon) where cells were co-transfected with Tet-on bAP::SEP::GluA2 and transactivator plasmids by 
single-cell electroporation (SCE)34. In some experiments, soluble tdTomato was also co-transfected to 
aid visualization of transfected cells. Before commencing SCE, the microscope chamber was washed 
with 70 % ethanol and allowed to dry. A face mask was always used during the following procedures 
and hands were regularly washed with 70 % ethanol. During SCE, the chamber contained sterile-filtered 
bicarbonate-containing Tyrode's solution maintained at ambient temperature and atmospheric 
conditions without perfusion. Bicarbonate-containing Tyrode’s solution was composed of (in mM): 
NaCl (145), KCl (3.5), CaCl2 (2.5), MgCl2 (1.3), HEPES (10), D-Glucose (10), NaHCO3 (2) and Na-
pyruvate (1) (pH 7.3, 300 mOsm). Patch pipettes (~8 Mohm) pulled from glass capillaries (GB150F-
8P, Science Products GmbH) were filled with potassium-based solution (in mM): K-methanesulfonate 
(135), NaCl (4), HEPES (10), EGTA (0.06), CaCl2 (0.01), MgCl2 (2), Na2-ATP (2) and Na-GTP (0.3) 
(pH 7.3, 280 mOsm) supplemented with plasmid DNA (total 10-33 ng/µL). After obtaining loose-patch 
seals, electroporation was achieved by delivering 12 V at 100-200 Hz for 0.25-0.5 s (pulse-width 0.25-
0.5 ms) using a constant voltage stimulus isolator (IsoFlex, A.M.P.I.). On returning slices to the 
incubator, culture media was supplemented with 10 µg/ml gentamicin, 1 µg/ml doxycycline and 10 µM 
D-biotin until experiments were preformed 2-3 weeks later. We attempted to electroporate 5-10 CA1 
neurons per slice with a typical success rate of 50 %. 
Organotypic slice electrophysiology 
On the day of the experiment, organotypic slices were transferred to a storage chamber containing 
carbogen-bubbled artificial cerebral spinal fluid (ACSF) (in mM): NaCl (125), NaHCO3 (25), NaH2PO4 
(1.25), KCl (2.5), CaCl2 (2), MgCl2 (2), D-Glucose (10) and Na-pyruvate (1). A dialysis device (3500 
M.W. cut-off, Slide-A-Lyzer MINI, Thermo Scientific) containing 0.25 ml of avidin Texas red 
conjugate was included in the storage chamber to quench free-biotin from the slices for at least 45 
minutes. For the X-link, slices were then individually transferred to a culture insert in a 35 mm culture 
dish containing 1 ml bicarbonate-containing Tyrode’s solution with 100 nM neutravidin (NA) and 
incubated at ambient temperature and atmospheric conditions for 45 minutes followed by washing in 
bicarbonate-containing Tyrode’s solution prior to electrophysiology experiments. For the control, 
incubation was without neutravidin (where the vehicle was Tyrode’s solution). Prior to any 
electrophysiological recordings of electrically evoked synaptic responses, CA3 was cut off to prevent 
seizures. The order of recordings was randomized for (blinded) neutravidin vs. vehicle pre-treatment 
experiments. 
For patch-clamp experiments, transfected Gria2-/- slices were then transferred to the microscope 
chamber perfused with carbogen-bubbled recording AACSF maintained at ~30 °C by an in-line solution 
heater (WPI). For recordings of LTP (Fig. 2), the AACSF contained (in mM): NaCl (125), NaHCO3 
(25), KCl (2.5), CaCl2 (4), MgSO4 (4), D-glucose (10), Na-pyruvate (1), picrotoxin (0.005), 2-
chloroadenosine (0.005), CGP-52432 (0.002) and ascorbic acid (0.25). A tungsten parallel bipolar 
stimulation electrode (~100 micron separation) was positioned in CA1 stratum radiatum close to the 
border with CA2. Electrode placement and patching was visually guided by observing the preparation 
with oblique illumination of infrared light through a 40x water immersion objective (NIR Apo 
40X/0.80W, Nikon) and 1-2X optical zoom. Patch pipettes (~5 Mohm) for whole-cell current clamp 
recordings were filled with potassium-based intracellular solution (recipe as described above for SCE) 
but with the addition of 0.15 mM spermine. After achieving a gigaohm seal, cells were maintained in 
cell-attached configuration for 5 minutes prior to breaking in. After opening the cell, stimulation (40 
μs) intensity (~10 V) and polarity were adjusted to obtain a small EPSP, mean peak amplitude 1.9 ± 
0.13 mV (mean ± s.d.). Analog voltage signals were filtered online at 10 kHz, digitized at 50 kHz and 
stored directly to the computer hard disk either using an EPC-10 USB controlled by Patchmaster 
software (HEKA Electronik) from a computer workstation running Windows XP (Microsoft), or using 
a MultiClamp 700B (Axon Instruments, Molecular Devices, LLC.) controlled by ACQ4 v0.9.3 
(http://www.acq4.org/) from a computer workstation running Windows 7 (Microsoft). Strictly 2 min 
after going whole-cell, the LTP recording was started and consisted of: 1) stimulation at 0.1 Hz for 2 
min to establish the baseline; 2) 100 Hz for 1 s repeated 3 times at 20 s intervals (HFS); and 3) 
stimulation at 0.1 Hz for 40 min to record post-HFS EPSP potentiation. For pseudo-HFS recordings, 
the stimulator was switched off during the induction protocol in step 2. Short baseline recordings were 
necessary to prevent washout of LTP in slice culture whole-cell recordings. The ensemble average 
obtained for every 3 traces was differentiated and filtered at 0.333 kHz (4-pole Bessel filter). The peak 
signal within 2-10 ms from the start of the stimulus artefact in the resulting traces corresponded to the 
steepest slope measurement, which is proportional to the underlying peak current (dV/dt µ I). These 
values were routinely normalised to the measured pre-artefact membrane potential to obtain more 
accurate slope measurements proportional to the underlying conductance. Peaks in the filtered first 
derivative had a latency of 4.6 ± 1.2 ms (mean ± s.d.) from the onset of the stimulation articant and 
were on average, an amplitude equating to 18.0 ± 8.0 (mean ± s.d.) standard deviations of the pre-
stimulus baseline noise. 
For whole-cell voltage clamp recordings of synaptic AMPAR rectification, AMPA/NMDA ratios and 
evoked EPSC amplitudes, the recording ACSF instead contained (in mM): NaCl (125), NaHCO3 (25), 
KCl (3.5), CaCl2 (5), MgCl2 (1), D-Glucose (10) and Na-pyruvate (1), picrotoxin (0.05), gabazine 
(0.002). Patch pipettes (~3-5 Mohm) for whole-cell voltage clamp recordings were filled with a 
caesium-based intracellular solution containing (in mM): Cs-methanesulfonate (135), NaCl (4), HEPES 
(10), QX-314 Cl (3), BAPTA (1), EGTA (0.6), CaCl2 (0.1), MgCl2 (2), Na2-ATP (2), Na-GTP (0.3) and 
spermine (0.15) (pH 7.3, 290 mOsm). Voltage clamp recordings were filtered online at 5 kHz and 
digitized at 25 kHz. For AMPA/NMDA ratios, ~30 evoked EPSCs were acquired and averaged at 
holding potentials of -70 and + 40 mV. The ratio was calculated from the peak current at -70 mV over 
the current measured at +40 mV with a delay of 50 ms after the start of the stimulus artefact. In 
recordings of synaptic AMPAR rectification only, ACSF was further supplemented with 0.1 mM D-
APV to inhibit NMDAR-mediated currents and ~30 evoked EPSCs were acquired and averaged at 
holding potentials of -60, + 30 and 0 mV. After subtraction of 0 mV traces, rectification index was 
calculated as the ratio of peak conductance measurements at +30 mV over -60 mV. For basal 
transmission, peak synaptic conductance measurements were obtained from evoked EPSCs recorded at 
holding potentials between -70 and -60 mV using stimulation intensities of ~10 V. In all voltage clamp 
recordings, a calculated and experimentally verified liquid junction potential of approximately +9 mV 
was corrected online. 
For single-photon glutamate uncaging, voltage clamp recordings were performed at room temperature 
without bath perfusion, in Tyrode’s solution (recipe as described above for SCE) supplemented with 
(in mM): MNI-glutamate (0.5), D-APV (0.1), picrotoxin (0.05), cyclothiazide (0.02) and TTX (0.001), 
(pH 7.3, 300 mOsm). A caesium-based intracellular solution used was as described above for voltage 
clamp recordings but without BAPTA and with 0.001 mM MK-801(+). Single-photon glutamate 
uncaging was achieved by pulses (5 ms) of a 405 nm laser (0.4 mW) focused through a 60x water 
immersion objective (NIR Apo 60X/1.00W, Nikon). The laser spot position was positioned with 
galvanometric mirrors by a FRAP head (Roper) controlled using ILAS system software in Metamorph 
(Molecular devices). Rectification was measured and calculated as described above for synaptic 
recordings. 
Whole-cell recordings of NMDAR-mediated currents were evoked by electrical stimulation of the 
Schaffer Collaterals. Recordings were performed at 30-32 °C and a holding potential of -60 mV. The 
recording aCSF contained (in mM): NaCl (125), NaHCO3 (25), KCl (2.5), CaCl2 (4), MgCl2 (4), D-
glucose (10) and Na-pyruvate (1), picrotoxin (0.05), NBQX (0.01), gabazine (0.002) and CGP-52432 
(0.002). Patch pipettes (~3-5 Mohm) were filled with a caesium-based intracellular solution containing 
(in mM): Cs-methanesulfonate (135), NaCl (4), HEPES (10), QX-314 Cl (3), EGTA (0.6), CaCl2 (0.1), 
MgCl2 (2), Na2-ATP (2) and Na-GTP (0.3) (pH 7.3, 290 mOsm). Decay of the EPSC currents were fit 
by a 2-component exponential decay with offset initially using the Chebyshev algorithm, where the fit 
parameters were then used as starting values for further optimization by the Levenberg-Marquardt 
algorithm. 
Throughout the paper, for clear presentation the stimulus artefact was blanked out. Slice 
electrophysiology data was analysed in Stimfit v0.13 
(https://github.com/neurodroid/stimfit/wiki/Stimfit) using custom python modules (see Code 
availability). 
 
Confocal imaging in slice culture 
Organotypic slices were prepared, transfected, dialysed and pre-treated with biotin-binding protein as 
for the experiments illustrated in Fig. 2, except that we used 500 nM AlexFluor(AF)-633 conjugate of 
Streptavidin (Molecular Probes) instead of unlabelled neutravidin.  After 45 minute incubation with 
Streptavidin AF-633, slices were washed in Tyrodes solution (3 x 15 minutes) and fixed with 4 % 
paraformaldehyde / 0.2% glutaraldehyde in PBS. Slices were then washed in PBS and water before 
mounting between a glass slide and coverslip with Fluoromount-G mounting medium (Southern 
Biotech). Samples were imaged through a 63x oil objective with the same spinning disk confocal 
microscope described for the FRAP experiments. Streptavidin AF-633, tdTomato and 
bAP::SEP::GluA2 and were excited sequentially at each 0.2 micron Z-step using 635, 532 and 473 and 
nm lasers respectively. Emitted light was captured with 100 ms exposure times and each Z-step image 
represents an average of 50 frames. 
 
Acute slice electrophysiology 
For field recordings, we prepared hippocampus-containing acute slices from C57BL6/J mice (8-9 weeks 
old). Briefly, mice were anesthetized with a mixture of ketamine/xylazine (100 and 10 mg/kg, 
respectively), and cardiac-perfused with ice-cold, oxygenated sucrose-based solution containing (in 
mM): 220 Sucrose, 2 KCl, 26 NaHCO3, 1.15 NaH2PO4, 10 Glucose, 0.2 CaCl2, 6 MgCl2. The brains 
were rapidly removed, and cut in the same sucrose-based solution using a vibratome (VT1200S, Leica 
Microsystems, USA). Sagittal slices (350µm) were transferred to an incubation chamber for 45 min at 
34 ºC, which contained a recording ACSF solution (mM): 124 NaCl, 3 KCl, 26 NaHCO3, 1.25 
NaH2PO4, 10 Glucose, 2 CaCl2, 1 MgCl2. After incubation, the slices were maintained at room 
temperature in oxygenated ACSF for at least 30 min.  
Hippocampal slices were recorded in a perfusion chamber continuously perfused with warm (33.5 °C), 
carbogen (95% O2 / 5% CO2)-bubbled recording ACSF using a peristaltic pump (Ismatec, 
Switzerland). A bipolar twisted platinum/iridium wire electrode (50µm diameter, FHC Inc., USA) was 
positioned in stratum radiatum of CA1 region, allowing the afferent schaffer collateral-commissural 
pathway from the CA3 to CA1 region to be stimulated. The field-EPSPs (fEPSPs) were recorded from 
stratum radiatum of CA1 area, using glass electrode (2~3 Mohm) pulled from borosilicate glass tubing 
(Harvard Apparatus, USA; 1.5 mm O.D x 1.17 mm I.D) and filled with ACSF. Pulses were delivered 
at 10s intervals by Clampex 10.4 (Molecular Devices, USA), and current was set using a stimulus 
isolator (Isoflex, AMPI, Jerusalem, Israel) to obtain 30-40 % of the maximum fEPSP. To induce LTP 
we used either a high-frequency stimulus (HFS, 1s at 100 Hz) repeated 3 times with an interval of 20 s, 
or theta burst stimuli (TBS) consisting of ten bursts (4 pulses at 100 Hz) repeated at 5Hz a delivered 
four times with 10 s intervals. Data were recorded with a Multiclamp700B (Axon Instruments, USA) 
and acquired with Clampex 10.4. The slope of the fEPSP was measured using clampfit with all values 
normalized to a 10 min baseline period. All experiments done with field recording were with no 
pharmacology.  
For whole cell recordings, mice were cardiac-perfused with ice-cold, carbogen (95% O2 / 5% CO2)-
bubbled NMDG-based cutting solution containing (in mM): 93 NMDG, 93 HCl, 2.5 KCl, 1.2 NaH2PO4, 
30 NaHCO3, 25 Glucose, 10 MgSO4, 0.5 CaCl2, 5 sodium ascorbate, 3 sodium pyruvate, 2 thiourea and 
12 mM N-acetyl-L-cysteine (pH 7.3–7.4, with osmolarity of 300–310 mOsm). The sagittal slices 
(350µm) were prepared in the ice-cold and oxygenated NMDG cutting solution described above, then 
transferred to an incubation chamber containing the same NMDG cutting solution for 15 min at 34 ºC. 
Before recording, the slices were maintained at room temperature for at least 45 min in carbogen (95% 
O2 / 5% CO2)-bubbled ACSF containing (mM): 92 NaCl, 2.5 KCl, 1.2 NaH2PO4, 30 NaHCO3, 20 
HEPES, 25 glucose, 2 MgSO4, 2 CaCl2, 5 sodium ascorbate, 3 sodium pyruvate, 2 thiourea and 12 mM 
N-acetyl-L-cysteine (pH 7.3–7.4, with osmolarity of 300–310 mOsm) 
After the CA3 region were cut off, the hippocampal slices were recorded in a perfusion chamber and 
continuously perfused with warm (33.5 °C), carbogen (95% O2 / 5% CO2)-bubbled recording ACSF 
(mM): 124 NaCl, 2.7 KCl, 2 CaCl2, 1.3 MgSO4, 26 NaHCO3, 1.25 NaH2PO4, 18.6 glucose, and 2.25 
ascorbic acid. Neurons in the CA1 region were visually identified with infrared videomicroscopy using 
an upright microscope equipped with a 60x objective. Patch electrodes (4–5 Mohm) were pulled from 
borosilicate glass tubing and filled with a low-chloride solution containing (in mM): 140 Cs-
methylsulfonate, 5 QX314-Cl, 10 HEPES, 10 phosphocreatine, 4 Mg-ATP and 0.3 Na-GTP (pH 
adjusted to 7.25 with CsOH, 295 mOsm). To evoke the EPSCs response, the stimulating electrode was 
positioned in stratum radiatum of CA1 region. All whole-cell recording experiments were performed in 
the presence of gabazine (10µM) to block the GABA-A receptors. To acquire the AMPA- and NMDA-
EPSCs ratios, the ratio was calculated from the peak current at -70 mV over the current measured at 
+50 mV with a delay of 200 ms after the start of the stimulus artefact. For recording the NMDA-EPSCs, 
CNQX (50µM) was also included in the recording ACSF. 
For antibody application, prior to field recording or whole cell recording, an injecting pipette (2~3 
Mohm) was filled with either α-GluA2 Fab (0.29 mg/ml dissolved in ACSF), α-GluA2 IgG (0.29 mg/ml 
dissolved in ACSF) or ACSF vehicle, and infused into the stratum radiatum at CA1 region by using a 
constant air-pressure (55-65 mbar) maintained in a tubing (1~1.2m length, 0.8mm ID) connected with 
a 1ml syringe. After 30 min of injection, we removed the injection pipette, and started field recording 
in the injected area and the whole-cell recording in the CA1 cellular area. In the continuous injection of 
antibody, one injecting pipette remained in CA1 area with constant infusion, and the other field 
recording pipette was put close to the tip of injecting one. The experimenter was blind to the antibody 
solution used in the experiments.  
 
In vivo electrophysiology 
Field excitatory postsynaptic potentials (fEPSP) measured in CA1 of the right hemisphere were evoked 
by stimulation of fibres projecting from the contralateral CA3 as described previously23. Briefly, 
stereotaxic surgery for electrophysiology experiments was performed under isoflurane anaesthesia (1.0-
1.2 %, O2 flow rate: 1L/min). Mouse body temperature was maintained using at 37 °C using a 
temperature control system (FHC, ME, USA). Concentric bipolar stimulating electrodes (Rhodes 
Medical Instruments, CA, USA) were inserted into the VHC (anteroposterior: -0.5 mm from bregma, 
mediolateral: +0.3 mm from midline on the left hemisphere; dorsoventral: 2.3 mm from brain surface). 
Forty-five minutes before HFS (1 train of 1 s at 100 Hz), α-GluA2 Fab (0.58 mg/ml), α-GluA2 IgG 
(0.58 mg/ml) or α-Rat IgG (0.36 mg/ml) was infused into the dorsoventral axis of CA1 area (3 
consecutive infusions of 60 nL at 30 s intervals at 1.0, 1.25 and 1.5 mm from brain surface) using 
controlled pressure-pulses of compressed air (20 psi, 2 min period, 180 nL total volume) applied via a 
Picospritzer® (Parker Hannifin, NJ, USA) through a single ejection-micropipette. The experimenter 
was blind to the antibody solution used in the experiments. fEPSPs were recorded through a glass 
recording electrode, filled with 0.5 M sodium acetate / 2% pontamine sky blue and positioned in area 
CA1 stratum radiatum (anteroposterior: -1.8 mm from bregma, mediolateral: -1.25 mm from midline 
on the right hemisphere; dorsoventral: 1.2-1.4 mm from brain surface).  
Voltage recordings of fEPSPs were amplified (Axoclamp2B amplifier, Molecular devices, CA, USA), 
filtered (differential AC amplifier, model 1700; A-M Systems, WA, USA), digitized and collected on-
line using a laboratory interface and software (CED 1401, SPIKE 2; Cambridge Electronic Design, 
UK). Test pulses (500 µs duration) were evoked using a square pulse stimulator and stimulus isolator 
(DS3; Digitimer, Hertfordshire, UK) every 2 s (corresponding to a 0.5Hz basal stimulation rate). 
Recordings were acquired at a 10 kHz sampling frequency and averaged over a 5 minute bin width. 
Basal stimulation intensity was adjusted to 30-40% of the current intensity that evoked a maximum 
field response. All responses were expressed as percent change of the average responses recorded during 
the 10 min before high frequency stimuli (HFS, 1 train of 1 s at 100 Hz). At the end of each recording 
experiment, the electrode placement was marked with an iontophoretic deposit of pontamine sky blue 
dye (20 µA, 30-min). To mark electrical stimulation sites, +50 µA was passed through the stimulation 
electrode for 2-min. Brains were rapidly removed, placed in dry ice before storage at -80°C. Coronal 
sections (40 µm-wide) were then cut using a Microm HM 500M cryostat (Microm Microtech, 
Francheville, France), stained with Neutral Red. 
Cannula implantation and antibody infusion 
Under continuous anesthesia with isoflurane, mice were positioned in stereotaxic apparatus (David 
Kopf Instruments, Tujunga, CA, USA), and treated with intraperitoneal buprenorphine (0.1 mg/kg) and 
local lidocaine (0.4 mL/kg of a 1% solution). Stainless steel guide cannulae (26 gauge; PlasticsOne, 
Roanoke, VA, USA) were bilaterally implanted above the hippocampus (from Bregma position, 
anteroposterior [AP] -1.8-2.0 mm, mediolateral [ML] ±2.2-2.5 mm, angled settings from 30º either side 
of vertical, dorsoventral [DV] 0.5-0.6 mm). Guide cannulae were anchored to the skull with dental 
cement (Super-Bond, Sun Medical Co. Lt, Japan). After the surgery, the mice recovered from 
anaesthesia on a 35ºC warm pad, and dummy cannulae were inserted into the guide to reduce the risk 
of infection. Infusion cannulae (33 gauge; connected to a 1 µL Hamilton syringe via polyethylene 
tubing) extended beyond the end of the guide cannulea by 2 mm to target the dentate gyrus (DG) of the 
dorsal hippocampus. Retracting the infusion cannulae by 1 mm enabled infusions directly into the CA1 
area. The antibodies (2.9 mg/ml in ACSF, see reagents) were infused bilaterally at a rate of 100 nL per 
min for a total volume of 500 nL (250 nL in the DG area, 250 nL in the CA1 area) per brain hemisphere, 
under the control of an automatic pump (Legato 100, Kd Scientific Inc., Hilliston, MA, USA). To allow 
penetration of drug, the injector was maintained for an additional 3 min at either site of DG and CA1. 
The mice were then transferred back to their cages to rest. After the behaviour experiments, to observe 
the location of the injection area brains were fixed by intracardiac perfusion with 4 % paraformaldehyde 
in PBS. Then slices (60 m) were immunostained, and imaged using an epifluorescence microscope 
(Leica DM5000, Leica Microsystems, Germany).  
 
Fear conditioning 
Mice were housed individually in a ventilation area before the start of behavioural training. Two weeks 
after surgery, the mice were handled for a further week. To reduce stress of the mice during subsequent 
experiments, they were trained by inserting and removing dummy cannulae several times each day. On 
day 1 of the experiment, animals were transferred to the conditioning context (Context A) for 
habituation. Both CS+ (30 s duration, consisting of 50 ms tones repeated at 0.9 Hz, tone frequency 7.5 
kHz, 80 dB sound pressure level) and CS− (30 s duration, consisting of white noise repeated at 0.9 Hz, 
80 dB sound pressure level) were presented 4 times with a variable interstimulus interval (ISI). On day 
2, the pre-conditioning group was injected 45-60 min before acquisition of both cued and contextual 
fear. For the post-conditioning group, infusion was immediately after acquisition (typically 5-10 min in 
practice). We proceeded with the conditioning phase in Context A as follows: 5 pairings of CS+ with 
the US onset coinciding with the CS+ offset (1 s foot shock, 0.6 mA, ISI 10–60 s). In all cases, 
CS− presentations were intermingled with CS+ presentations and ISI was variable over the whole 
training course. Contextual memory was tested 24 h after conditioning by analyzing the freezing levels 
at 60 - 120 s after mice were exposed in Context A. Cued memory was tested 30 hrs after conditioning 
by analyzing the freezing levels at the first CS+ presentations in Context B (recall) Additionally, we 
performed a pure contextual conditioning protocol, which typically consisted of 3 foot shocks of 0.6 
mA for 2 s with 60 s ISI. Discriminative contextual fear memory was tested 24 h after conditioning by 
analyzing the freezing levels in context C vs B. Freezing behavior was recorded in each behavioral 
session using a fire-wire CCD camera (Ugo Basile, Italy), connected to automated freezing detection 
software (ANY-maze, Stoelting, USA). The experimenter was blind to the antibody solution used in 
the experiments. Measurements of freezing behaviour were alternated between (blinded) experimental 
groups and the mice within each group were selected randomly.  
 
Biochemistry 
Hippocampal neurons from Sprague-Dawley rat embryos (E18) were plated at a density of 600,000 
cells / well in 6-well-culture plates. 5 µM Ara-C (Sigma-Aldrich) was added at DIV 3 and neurons were 
then fed twice a week with Neurobasal supplemented with SM1 supplement (Stemcell) and 2 mM 
Glutamine. 
 
At 14-16 DIV, neurons were rinsed with Tyrode’s buffer containing 1µM TTX, and then treated for 15 
min with the same buffer containing 10 µg/ml of an irrelevant antibody (anti-GFP whole IgG1-κ from 
murine clones 7.1 and 13.1 (11814450001, Roche)) as a control condition or with an anti-GluA2 IgG1-
κ for the crosslink condition. After 2 washes, cells were lysed in Lysis buffer (1% NP40, 0.5% DOC, 
0.02% SDS in PBS, 1X protease inhibitor cocktail (Roche) and 2X Halt Phosphatase Inhibitor Cocktail 
(Thermo Fisher Scientific)). Cell lysates were collected and spun down at 16,000g for 10 min. Protein 
concentration of each lysate was quantified using BCA reagent (Thermo Fisher Scientific) and 30 µg 
of protein per condition was loaded twice on SDS-PAGE, transferred to nitrocellulose membrane and 
blocked with Odyssey blocking buffer. Each membrane was incubated with mouse anti-N-terminus 
GluA1 (NeuroMab clone N355/1) and either anti-rabbit GluA1 Phospho Ser 831 (Millipore Cat. # 04-
823), or anti-rabbit GluA1 Phospho Ser 845 (Abcam Cat. # ab76321). Following incubation with 
secondary antibodies anti-mouse Alexa Fluor 680 and anti-rabbit Alexa Fluor 800, blots were imaged 
using an Odyssey Imaging System. Analysis was done using the Odyssey software and quantification 
of GluA1 phosphorylation level, normalized to GluA1, was performed using the average intensity of 
each single band. The experimenter was blind to the antibody solution used in the experiments. 
 
AMPAR endocytosis 
Cultured hippocampal neurons (17 DIV) were rinsed in Tyrode’s solution and then incubated in 10 
µg/mL anti GluA2 (clone 15F1) to crosslink AMPARs, or control (water or anti-GFP at 10 µg/mL, 
11814450001, Roche) for 15 minutes in the incubator. The experimenter was blind to the antibody 
solution used in the experiments.. Neurons were then rinsed with Tyrode’s and immediately live-stained 
for surface GluA1 (2 µg/mL for 6 minutes), using a rabbit polyclonal IgG raised against the extracellular 
region RTSDSRDHTRVDWKRC (Agro-Bio, France). 
 One set of coverslips was fixed immediately at time = 0 min, to know starting level of GluA1 on 
surface. The remaining coverslips were returned to the incubator for 30 minutes to allow basal 
endocytosis, and then fixed with 4% PFA and 4% sucrose in PBS for 15 minutes at RT. After fixation 
and rinsing with PBS, non-specific staining was blocked by 30 minute incubation in PBS containing 
1% BSA. Then surface-bound GluA1 antibody was revealed by incubation of un-permeabilized cells 
with Gt anti Rb CF568 (Biotium 20102) diluted to 4 µg/mL in blocking solution for 30 minutes. For 
acquisition, 12-15 cells per coverslip were selected in transmission to avoid bias from fluorescence 
signal, and imaged at 63x with identical acquisition settings. Background, defined as average 
fluorescence in an empty region of coverslip + 1 x St Dev, was subtracted from each image pixel. 
Fluorescence from cell bodies was omitted by ‘painting black’ regions encompassing cell bodies to 
allow quantification of dendrite fluorescence only. After background subtraction the average 
fluorescence of all pixels above background in each image was averaged. The identity of samples’ 
experimental treatment was revealed to experimenter after image analysis to avoid bias. 
 
Receptor tracking experiments 
For SPT experiments, dissociated neurons (13-14 DIV) were imaged at 37°C in an open Ludin Chamber 
(Ludin Chamber, Life Imaging Services, Switzerland) filled with 1 ml of Tyrode’s. ROIs were selected 
on the dendrites of cells expressing GFP fluorescence. ATTO-647 coupled to α-GluA2 IgG (clone 
15F1) was then added to the chamber at sufficient quantity to control the density of labelling. The 
fluorescence signal was collected using a sensitive EMCCD (Evolve, Photometric, USA). Acquisition 
was driven with MetaMorph software (Molecular Devices, USA) and exposure time was set to 20 ms. 
Around 10 000 frames were acquired in typical experiment, collecting up to few thousands of 
trajectories. Sample was illuminated in oblique illumination mode, where the angle of refracted beam 
varied smoothly and was adjusted manually to maximize signal to noise ratio. The main parameters 
determined from the experiments was the diffusion coefficient (D) based on the fit of the mean square 
displacement curve (MSD). Multi-colour fluorescence microspheres (Tetraspeck, Thermofisher, 
France) were used for image registration and drift compensation. SPT data analysis was reported before 
(Giannone et al., 2010; Nair et al., 2013). 
Quantum dot experiments are acquired on the same system. Neurons are transfected at DIV 10 with 
bAP-SEP-GluA2 construct. At DIV 13-14, neurons are pre-incubated for 5 minutes in a mix containing 
mouse anti-GFP, and then washed twice time with culture medium. A second incubation was then 
carried out in culture medium + 1% BSA supplemented with quantum dots coated with secondary anti 
mouse. After two washes, coverslips are amounted and observed for 30 minutes.  
Crosslinking was achieved by 15 minutes’ pre-incubation in either anti-GluA2 antibody or neutravidin 
in Tyrode’s solution. 
 
Statistical analysis 
The chosen sample size in most experiments satisfied the resource equation, where the error degrees of 
freedom in the General Linear Model (GLM) (e.g. the denominator of F in ANOVA) would reach 
between 10-20. Statistics were performed in Prism 6.04 (GraphPad Software, Inc.), SPSS Statistics 
(version 22, IBM) and in Matlab R2009b (MathWorks) using anovan, aoctool and multcomp functions 
from the Statistics and Machine Learning Toolbox (MathWorks, Inc.). To correct for violations of 
sphericity in repeated-measures ANOVA designs, adjustments to the degrees of freedom were carried 
out using the function epsilon (see Code availability). Corrections for multiple comparisons were 
carried out using the function multicmp (see Code availability). For N-way ANOVA in Matlab or 
General Linear Modelling (GLM) in SPSS, care was taken in appropriately nesting factors (where 
applicable) and assigning factors as ‘random’ or ‘fixed’. Interactions with blocking factors were not 
included in the ANOVA models. Sum-of-squares type III was used routinely except for 2-way ANOVA 
without interaction models, which used type II. Histograms, normal probability plots of N-way ANOVA 
model residuals and residuals vs model fit plots were routinely examined. Continuous dependent 
variables with a lower bound of 0 were routinely subjected to log10 transformation to satisfy assumptions 
of standard parametric statistical tests. Outliers were identified by Grubbs’ test with an alpha level of 
0.1, and instances where this occurred are described in the Figure statistics section. Most percentage 
time freezing data used for hypothesis testing was within 20-80 % range and required no transformation. 
Where parametric assumptions were not satisfied, tied-rank transformation were used instead. 
Statistical significance was considered at P < 0.05 except for interaction terms in N-way ANOVA tests, 
which were considered significant at P < 0.1 and were followed up with post-tests. Unless stated 
otherwise, all post-tests used the Holm-Bonferroni method. All graphs were plot in Prism 6.04. For 
graphing ANOVA results, marginal means and 84% confidence intervals (CI) or Fisher’s Least 
Significant Difference (LSD) error bars were calculated in SPSS and Matlab respectively; 84% CI and 
LSD error bars overlap at P > 0.05. Specific details of the statistical analysis are provided in the Figure 
statistics section. 
For analysis of normalized FRAP curves, the ensemble mean normalized spine FRAP curve was 
calculated for each cell, which was subsequently fit with the following equation: 
F(t) = Rmob * t / τ½ / ( 1 + ( t / τ½) ), 
where the first post-bleach image occurs at t = 0, F(t) is the normalized fluorescence at time t, Rmob is 
the mobile fraction and τ½ is the half-time of the recovery curve. Curve fitting to minimize the sum-of-
squared residuals was achieved using the Levenberg-Marquardt algorithm. Standard error bands were 
obtained by calculation of the standard error of the mean of the fitted data points at each time point. To 
analyse the Rmob, individual spine FRAP curves were fit using the above equation. Almost 90 % of spine 
FRAP curves were fit successfully and could be included in the analysis  
 
Figures statistics 
In all figures, statistics are summarised as: ns = not significant; * = p < 0.05; ** = p < 0.01; *** = p < 
0.01 
Figure 1d: The mobile fractions (Rmob) from fitting individual spine FRAP curves were analysed by 
mixed model nested ANOVA, where spine Rmob values were nested within cells (random) and 
compared between treatments (fixed). Treatment F(5,14.61) = 13.32, P = 5.26 x 10-5. Holm-
Bonferroni post-test results (comparing with the respective control for GluA1 or GluA2) are 
summarized in the figure. Mean ± standard deviation (n) of the spine mobile fractions for each 
treatment presented from left-to-right in the bar graph: 0.733 ± 0.320 (43), 0.293 ± 0.211 (49), 0.612 ± 
0.284 (25), 0.688 ± 0.197 (14), 0.551 ± 0.208 (19), 0.181 ± 0.097 (22). 
Figure 1e: Rectification index was log10-transformed and analyzed by 1-way ANOVA. Top, F(2,19) 
= 67.32, P = 2.38 x 10-9.	Bottom, F(2,19) = 107.81, P = 4.26 x 10-11. Holm-Bonferroni post-test results 
(comparing with wild-type untransfected cells) are summarized in the figure. Mean ± standard 
deviation (n) of the RI for each treatment presented from left-to-right in the top bar graph: -0.02 ± 
0.09 (5), -1.02 ± 0.23 (6), -0.14 ± 0.16 (11). Mean ± standard deviation (n) of the RI for each 
treatment (after log10-transformation) presented from left-to-right in the bottom bar graph: -0.06 ± 
0.09 (7), -1.54 ± 0.11 (6), -0.26 ± 0.28 (9).	
Figure 1f: Experiment replicates were treated as a blocking factor in 2-way ANOVA tests without 
interaction. Top. AMPA/NMDA ratios from 2 experiments, treatment F(1,8) = 0.0015, P = 0.97; 
Middle, evoked EPSCs from 7 experiments, treatment F(1,30) = 0.0014, P = 0.97; Bottom, glutamate 
uncaging responses from 3 experiments, treatment F(1,14) = 0.56, P = 0.468. The test results are 
summarized in the figure. Mean ± standard deviation (n) of the AMPA/NMDA ratio (after log10-
transformation) for each treatment presented from bottom-to-top in the top bar graph: 0.21 ± 0.18 (5), 
0.19 ± 0.30 (6). Mean ± standard deviation (n) of the synaptic conductance (after log10-transformation) 
for each treatment presented from bottom-to-top in the middle bar graph: -0.096 ± 0.306 (19), -0.001 ± 
0.287 (19). Mean ± standard deviation (n) of the somatic uncaged glutamate conductance (after log10-
transformation) presented from bottom-to-top in the bottom bar graph: 0.30 ± 0.47 (9), 0.17 ± 0.44 (9). 
Figure 2: EPSP slope data for LTP curves were categorized into baseline (all pre-HFS data), short-term 
potentiation (STP, 2-4 min post-HFS) and long-term potentiation (LTP, 32-37 min post-HFS). The first 
2 min after the start of the HFS was not included in the STP category to avoid potential contamination 
by presynaptic post-tetanic potentiation (PTP). Log10 EPSP slope measurements were compared 
between these time categories by 1-way repeated measures (RM)-ANOVA with Greenhouse-Geisser 
correction for violations of sphericity. A significant result from RM-ANOVA was followed up with 
Holm-Bonferonni post-tests.  
Figure 2a: 1-way RM-ANOVA, F(1.71,11.99) = 10.99, P = 0.0026. Holm-Bonferroni post-test results 
(comparing with baseline) are summarized in the figure.  
Figure 2b: 1-way RM-ANOVA, F(1.54,12.33) = 9.04, P = 0.0058. Holm-Bonferroni post-test results 
(comparing with baseline) are summarized in the figure. 
Figure 2c: 1-way RM-ANOVA, F(1.31,9.18) = 13.53, P = 0.00334. Holm-Bonferroni post-test results 
(comparing with baseline) are summarized in the figure.  
Figure 2d: 1-way RM-ANOVA, F(1.54, 9.25) = 0.55, P = 0.55. The ANOVA result is summarized in 
the figure. 
Figure 2e: 1-way RM-ANOVA, F(1.54,12.30) = 0.29, P = 0.6968. The ANOVA result is summarized 
in the figure. 
Figure 3b-c: 1-way RM-ANOVA was as described for Figure 2. To compare the antibody treatments, 
average fEPSP slope measurements during the STP and LTP time periods were expressed as % of 
baseline, then log10 transformed and analysed by 2-way ANOVA with repeated measurements (RM) in 
each cell recording (random) to test for an interaction between treatment (fixed) and plasticity (fixed, 
STP vs LTP).  
Figure 3b: 1-way RM-ANOVA: Fab HFS, F(1.77,8.85) = 16.89, P = 0.0011; IgG HFS, F(1.85,12.95) 
= 0.3766, P = 0.6777. 2-way RM-ANOVA: Treatment x Plasticity, F(1,12) = 0.031, P = 0.864; 
Treatment, F(1,12) = 16.17, P = 0.0017; Plasticity F(1,12) = 1.20, P = 0.295. 
Figure 3c: 1-way RM-ANOVA, Fab TBS, F(1.10,5.51) = 39.56, P = 0.0009; IgG TBS, F(1.19,5.96) = 
7.26, P = 0.0331. 2-way RM-ANOVA: Treatment x Plasticity, F(1,12) = 0.0179, P = 0.864. 
Figure 3h: fEPSP slope potentiation was measured as the average normalised fEPSP slope 10-40 
minutes post-HFS. The log10 transform of the fEPSP slope potentiation was compared between the 
antibody conditions using 1-way ANOVA: F(2,18) = 7.675, P = 0.0039. Pairwise Holm-Bonferroni 
post-test results are summarized in the figure. Note that a data point in the GluA2 IgG treatment of our 
original data set had particularly low potentiation (26.6%). It was a significant outlier according to 
Grubbs’ test, and so was removed from the graph and the analysis.  
Figure 4: The time the mice spent freezing was expressed as a % of observation time. The % freezing 
data was analysed by 2-way ANOVA with repeated measurements (RM) in each mouse (random) to 
test for an interaction between antibody treatment (fixed) and test (fixed).  
Figure 4a1: A significant interaction (P < 0.1) was followed up by Holm-Bonferroni post-tests. 2-way 
RM-ANOVA: Antibody x Test, F(2,24) = 3.13, P = 0.0622. Pairwise Holm-Bonferroni post-test results 
are summarized in the figure. 
Figure 4a2: Analysis was performed on rank-transformed % freezing data to satisfy the parametric 
assumption of normality. 2-way RM-ANOVA: Antibody x Stimulus F(2,24) = 0.12, P = 0.889. 
Antibody F(2,24) = 1.01, P = 0.3801.	Stimulus F(1,24) = 29.36, P = 1.445 x 10-5. The test results for 
the main effects are summarized in the figure. 
Figure 4b: Since the number of tests were > 2, the P-values for Mouse, Test and Test x Antibody effects 
were corrected for violations of multi-sample sphericity by Huynh-Feldt-Lecoutre adjustment of the 
degrees of freedom. 2-way RM-ANOVA: Antibody x Test, F(1.76,36.85) = 0.07, P = 0.909; Antibody 
F(1,21) = 1.09, P = 0.3087; Test F(1.76,36.85) = 5.67, P = 0.0093. The test results for the main effects 
are summarized in the figure. 
Extended Data Figure 1: Middle, 1-way ANOVA of the mean mobile fraction per cell followed by 
Holm-Bonferroni post-tests: F(2,19) = 11.84, P = 0.0005. Holm-Bonferroni post-test results (comparing 
with control) are summarized in the figure. 
Extended Data Figure 2b-c: Analysis as described for Figure 2.  
Extended Data Figure 2b: 1-way RM-ANOVA, F(1.57,10.97) = 0.61, P = 0.53. The ANOVA result 
is summarized in the figure. 
Extended Data Figure 2c: 1-way RM-ANOVA, F(1.77,12.40) = 2.89, P = 0.098.. The ANOVA result 
is summarized in the figure. 
Extended Data Figure 2d-e: Analysis is of data from the same cells recorded in Fig 2a and b. However, 
to include blocking (and thus increase the power for comparison between treatments) two NA 
recordings could not be included since the data for the control was missing from one experiment block. 
Extended Data Figure 2d: The Area-Under-Curve (AUC) of postsynaptic HFS train responses were 
calculated as the trapezium (linear) integral of baseline-subtracted traces for a 1.1 s period following 
the first stimulus artefact. The AUC measurements were compared using mixed model nested ANOVA 
testing treatment (fixed, Ctrl vs NA) and train (fixed, HFS 1-3) main effects with interaction between 
treatment x train. Cell measurements (random) were nested within 4 experiment blocks (random) and 
treatments. The P-values for cell, train and train x treatment effects were corrected for violations of 
multi-sample sphericity by Huynh-Feldt-Lecoutre adjustment of the degrees. Train x Treatment 
F(1.11,14.45) = 2.35, P = 0.145, Treatment F(1,10) = 0.02, P = 0.883, Train F(1.11,14.45) = 0.0355. 
For graphing, the data was re-analysed as an ordinary 3-way ANOVA with treatment x train interaction. 
The marginal means were then plot with Fisher’s LSD error bars, which overlap at P > 0.05 for the 
difference between treatments (Ctl vs. NA). The test results for the main effects are summarized in the 
figure. Mean ± standard deviation (n) of the depolarization AUC (after log10-transformation) presented 
from bottom-to-top in the bar graph: 1.24 ± 0.33 (7), 1.33 ± 0.14 (8), 1.28 ± 0.32 (7), 1.41 ± 0.18 (8), 
1.28 ± 0.31 (7), 1.44 ± 0.18 (8). 
Extended Data Figure 2e: The average EPSP slopes during the baseline recordings from experiments 
in Fig. 2a-b were compared by 2-way ANOVA (4 experiment blocks) without interaction. Treatment 
F(1,10) = 0.35, P = 0.57. The test result is summarized in the figure. Mean ± standard deviation (n) of 
the EPSP slope (after log10-transformation) presented from bottom-to-top in the bar graph: -0.34 ± 0.15 
(7), -0.29 ± 0.11 (8). 
Extended Data Figure 2f: Linear regression through the origin included 95 % confidence bands. 
Measurements from transfected and untransfected cells were log10-transformed and compared using 
paired t-tests. top left, t(5) = 2.28, P = 0.071; top right, t(6) = 0.28, P = 0.7867; bottom left, t(5) = 0.053, 
P = 0.96; bottom right, t(6) = 1.87, P = 0.11. 
Extended Data Figure 3: Analysis as described for Figure 2. 
Extended Data Figure 3a: We had a notable upward sloping baseline in the ensemble mean of our 
original sample set (9 recordings). To exclude the possibility that run-up was responsible for the 
potentiation observed in this instance, we performed a correlation analysis on the baseline period of all 
the recordings in this figure panel and excluded any recordings with an absolute Pearson’s correlation 
coefficient (r) > 0.5. Three recordings were removed based on this criterion. F(1.74,8.70) = 10.2, P = 
0.0062. Holm-Bonferroni post-test results are summarized in the figure. 
Extended Data Figure 3b: 1-way RM-ANOVA, F(1.52,3.04) = 14.66, P = 0.029. Holm-Bonferroni 
post-test results are summarized in the figure. 
Extended Data Figure 3c: 1-way RM-ANOVA, F(1.03,7.19) = 1.07, P = 0.3369. The ANOVA result 
is summarized in the figure. 
Extended Data Figure 4a: Unpaired two-tailed Student t-test on log10-transformed PPR of EPSP slope, 
t(15) = 0.62, P = 0.4573. 
Extended Data Figure 4b: An outlier (in NA pre-treatment: PPR = 3.214) was detected by Grubbs’ 
test and removed from the graph and the analysis. Unpaired two-tailed Student t-test on log10-
transformed PPR of EPSC amplitude, t(7) = 2.04, P = 0.081. 
Extended Data Figure 5: Average EPSP slope measurements during the STP and LTP time periods 
from the experiment in Fig. 2a-e, Extended Data Fig. 2b-c and Extended Data Fig. 3a-c were expressed 
as % of baseline, then log10 transformed and analysed by 2-way ANOVA with repeated measurements 
(RM) in each cell recording (random) to test for an interaction between treatment (fixed) and plasticity 
(fixed, STP vs LTP). Treatment x Plasticity F(9,64) = 7.42, P = 2.5e-07. Benjamini and Hochberg post-
tests were used for comparisons against the control group (+AP+HFS) while considering STP and LTP 
as separate families. For graphing, the marginal means were plot with Fisher’s LSD error bars, which 
overlap at P > 0.05 for the difference between treatments. The results of Benjamini and Hochberg post-
tests (controlling the false discovery rate at 5%) are summarized in the figure. 
Extended Data Figure 6a: Analysis as described for Fig. 1c.  
Extended Data Figures 6b-c: Right, mobile fractions were compared by unpaired two-tailed Student’s 
t-tests.  
Extended Data Figure 6b: Right, t(22)=4.18, P = 0.0004. 
Extended Data Figure 6c: Right t(13)=1.095, P = 0.2935. 
Extended Data Figure 7a: Fluorescence at 30 minutes after feeding was normalized to the mean of 
the fluorescence obtained from coverslips fixed at time zero for the respective treatment within each 
experiment. To compare the normalized immunolabelling between the two treatments, we used mixed 
model nested ANOVA, in which we used normalised fluorescence intensity for field-of-views (FOVs) 
per coverslips (random) nested within experiment block (random) and both fixed factors (antibody and 
time). Data is from 2 experiments; in each experiment, we imaged multiple FOVs across 2 coverslips 
per treatment. Time x Antibody, F(1,194) = 0.91, P = 0.3594; time, F(1,194) = 200.2, P = 1.91 x 10-8. 
The test results for the interaction and the main effect (time) are summarized in the figure. Mean ± 
standard deviation (n) of the normalised fluorescence intensity (after log10-transformation) presented 
from left-to-right in the right bar graph: 0.00 ± 0.11 (53), -0.42 ± 0.10 (48), 0.00 ± 0.11 (55), -0.37 ± 
0.15 (54). 
Extended Data Figure 7b: Western blot band intensities were normalised to the mean of the control 
(a-GFP). 2-way ANOVA without interaction was used to test the effect of antibody (fixed) on band 
intensities within each of the 3 experiment blocks (random).  Bottom left, F(1,8) = 1.44, P = 0.2645. 
Bottom right, F(1,8) = 0.06, P = 0.8055. The test results are summarized in the figure. Mean ± standard 
deviation (n) of the normalised band intensities (after log10-transformation) presented from left-to-right 
in the left bar graph: 0.00 ± 0.031 (6), -0.003 ± 0.032 (6). Mean ± standard deviation (n) of the 
normalised band intensities (after log10-transformation) presented from left-to-right in the right bar 
graph: 0.00 ± 0.050 (6), -0.019 ± 0.063 (6). 
Extended Data Figure 7c: Western blot band intensities were normalised to the mean of the control 
within each antibody treatment. 2-way RM-ANOVA was used to test the effect of antibody (fixed) and 
cLTP treatment (fixed) on band intensities within each of the 9 experiment blocks (random). 
Interactions with blocking factors were not included in the ANOVA model. Treatment x Antibody, 
F(1,24) = 2.11, P = 0.1584; Treatment, F(1,24) = 52.88, P = 1.64 x 10-7. The test results for the 
interaction and the main effect (treatment) are summarized in the figure. Mean ± standard deviation (n) 
of the normalised band intensities (after log10-transformation) presented from left-to-right in the bar 
graph: 0.000 ± 0.131 (9), 0.077 ± 0.138 (9), 0.000 ± 0.132 (9), 0.051 ± 0.130 (9). 
Extended Data Figure 8a: Log10 transformed PPR (during 1 min following HFS) is not significantly 
affected by AMPAR X-link: Unpaired two-tailed Student t-test, t (12) = 0.63, P = 0.54. 
Extended Data Figure 8c-d: Input-output curves for stimulation intensities > 0.3 mA were analysed 
by 1-way ANCOVA following log10 transformation of both the x and y axis variables.  
Extended Data Figure 8c: 1-way ANCOVA: Antibody x log10(intensity) F(2,252) = 0.06, P = 0.9372, 
Antibody F(2,252) = 0.67, P = 0.5125, Intensity F(1,252) = 96.16, P = 0. 
Extended Data Figure 8d: Whole-cell recordings from cells within the same slice were averaged 
before performing statistics. 1-way ANCOVA: Antibody x log10(intensity) F(2,59) = 0.1, P = 0.9067, 
Antibody F(2,59) = 0.1, P = 0.9017, Intensity F(1,59) = 15.96, P = 0.0002. 
Extended Data Figure 8e-f: Whole-cell recordings from cells within the same slice were averaged 
before performing statistics. Data were analysed by 1-way ANOVA after log10-transformation. 
Extended Data Figure 8e: 1-way ANOVA: Middle, F(2,26) = 0.18, P = 0.8324. Right, F(2,26) = 0.59, 
P = 0.5627. 
Extended Data Figure 8f: 1-way ANOVA: F(2,54) = 0.53, P = 0.5942. 
 
Code availability 
Custom python code used for protocols and analysis are available at GitHub (v0.1, 
https://github.com/acp29/penn). Custom Matlab code for additional statistical functions (multicmp and 
epsilon, both v1.0) are available from Matlab Central File Exchange (#61659 and #61660 respectively). 
 
Data availability  
The data that support the findings of this study are available from the corresponding author upon 
reasonable request.  
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